Compare MOD & BMRN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MOD | BMRN |
|---|---|---|
| Founded | 1916 | 1996 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Auto Parts:O.E.M. | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 11.4B | 10.0B |
| IPO Year | 1995 | 1999 |
| Metric | MOD | BMRN |
|---|---|---|
| Price | $201.64 | $54.69 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 6 | 18 |
| Target Price | ★ $212.67 | $88.22 |
| AVG Volume (30 Days) | 1.0M | ★ 1.8M |
| Earning Date | 05-19-2026 | 04-30-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 12.87 | N/A |
| EPS | 0.90 | ★ 1.80 |
| Revenue | ★ $1,352,500,000.00 | $1,313,646,000.00 |
| Revenue This Year | $23.05 | $14.30 |
| Revenue Next Year | $21.83 | $11.65 |
| P/E Ratio | $237.12 | ★ $30.08 |
| Revenue Growth | N/A | ★ 17.62 |
| 52 Week Low | $64.79 | $50.76 |
| 52 Week High | $243.80 | $70.63 |
| Indicator | MOD | BMRN |
|---|---|---|
| Relative Strength Index (RSI) | 47.65 | 37.96 |
| Support Level | $125.19 | $54.35 |
| Resistance Level | $239.41 | $56.21 |
| Average True Range (ATR) | 12.22 | 1.60 |
| MACD | 0.13 | -0.32 |
| Stochastic Oscillator | 30.89 | 17.03 |
Modine Manufacturing Co provides thermal management solutions to diversified markets and customers. The company provides engineered heat transfer systems and heat transfer components for use in on- and off-highway original equipment manufacturer (OEM) vehicular applications in the United States. It offers powertrain cooling products, such as engine cooling assemblies, radiators, condensers, and charge air coolers; auxiliary cooling products, including power steering and transmission oil coolers. Its operating segments include Climate Solutions and Performance Technologies.
BioMarin is a global biotechnology company focused on developing and commercializing therapies for rare genetic diseases. BioMarin specializes in enzyme replacement therapies, gene therapies, and other advanced treatments designed to address complex genetic disorders. The company has eight approved therapies for conditions including achondroplasia, phenylketonuria, hemophilia, and mucopolysaccharidosis. BioMarin has an expanding, yet relatively early-stage, pipeline of treatments in development across skeletal conditions and enzyme therapies.